Gaps Found In Most Pharma Trial Diversity Policies
Executive Summary
A study suggests industry groups like PhRMA could use more of their influence to hold members accountable on trial diversity policies.
Topics
- Subjects
- Clinical Trials
- Diversity & Inclusion
- Regulation
- Research & Development
- Regions
- North America
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PS155086
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
PS155086
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.